• Edit
Get premium to view all results
DateInvestorsAmountRound
-investor investor investor investor investor investor investor

€0.0

round
investor investor

€0.0

round
investor

€0.0

round
investor investor

€0.0

round
investor investor

€0.0

round
investor

€0.0

round
investor investor investor investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
N/A

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor

€0.0

round
investor investor

€0.0

Valuation: €0.0

round
investor investor investor

€0.0

Valuation: €0.0

round
investor

€0.0

Valuation: €0.0

round
N/A

€0.0

Valuation: €0.0

round
N/A

€0.0

round
N/A

€0.0

round
investor investor

€0.0

round
investor investor investor investor investor

€0.0

Valuation: €0.0

round
investor

€0.0

Valuation: €0.0

round
N/A

€0.0

Valuation: €0.0

round
investor

€0.0

round
*

£50.0m

Post IPO Equity
Total Funding000k

Financials

Estimates*

Get premium to view all results
Edit
Revenues, earnings & profits over time
USD2021202220232024202520262027
Revenues0000000000000000000000000000
% growth17 %49 %(15 %)8 %20 %28 %27 %
EBITDA0000000000000000000000000000
% EBITDA margin(104 %)(31 %)(64 %)(50 %)(44 %)(24 %)(8 %)
Profit0000000000000000000000000000
% profit margin(125 %)(46 %)(91 %)(80 %)(65 %)(43 %)(22 %)
EV0000000000000000000000000000
EV / revenue00.0x00.0x00.0x00.0x00.0x00.0x00.0x
EV / EBITDA00.0x00.0x00.0x00.0x00.0x00.0x00.0x
R&D budget0000000000000000000000000000
R&D % of revenue57 %33 %61 %54 %---

Source: Company filings or news article, Equity research estimates

More about Oxford Nanopore Technologies
Edit

Oxford Nanopore Technologies is a biotech company that specializes in the development of nanopore sequencing technology. This technology is used to decode DNA and RNA, providing highly accurate genomic data. The company's technology is used by scientific researchers to answer questions about the biology of people, plants, animals, pathogens, and environments. It is also increasingly being used in applied settings such as healthcare and food safety.

The company's business model is based on selling its nanopore sequencing technology and related products, including flow cells, compatible devices, manual and automated library prep, and data analysis solutions. The technology provides real-time insights, allowing for faster results that don't require batching. This makes it accessible and affordable, with scalability that enables more use cases.

The company operates in the biotech market, serving clients in the scientific research community, healthcare sector, and food safety industry. Its technology is unique in that it offers any-length sequencing, from short to ultra-long native DNA and RNA reads. This provides richer insights as it captures more types of genetic variation.

In terms of financial performance, the company generates revenue through the sale of its products and services. It has also formed strategic partnerships, such as with Apple, to integrate its technology with the M3 silicon chip.

Keywords: Nanopore Sequencing, Genomic Data, Biotech, Scientific Research, Healthcare, Food Safety, DNA and RNA Decoding, Real-time Insights, Scalability, Technology Sales.

Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.
Book a Demo

Investments by Oxford Nanopore Technologies

Edit
Northern Nanopore Instruments
ACQUISITION by Oxford Nanopore Technologies Nov 2023